Servicio de Salud Mental, Hospital de Jerez de la Frontera, Cádiz, Spain.
Servicio de Farmacia, Hospital Juan Ramón Jiménez, Huelva, Spain.
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jun 8;108:110088. doi: 10.1016/j.pnpbp.2020.110088. Epub 2020 Sep 2.
This paper evaluates gender bias in the published clinical trials of Vortioxetine. We conducted a systematic review of controlled clinical trials of Vortioxetine for the treatment of depression. The literature search was performed using MEDLINE and following the corresponding international recommendations. We identified 42 articles, of which 23 were included. The proportion of women ranged from 47%-75% and the percentage of women included in the 10,404 total patients sample was 65%. The separate analysis of the main variable between the subpopulations of men and women was only carried out in 3/23 publications included. In contrast, 6/23 trials analyzed secondary variables separated by sex. No trials discussed the results separately by sex. The proportion of women included was slightly higher than that in clinical trials of other antidepressants. However, the analysis of the main result or secondary variables by sex, as well as discussing the results separately by sex, are scarce. This gives rise to gender bias in these works.
本文评估了伏硫西汀已发表的临床试验中的性别偏见。我们对伏硫西汀治疗抑郁症的对照临床试验进行了系统评价。文献检索使用了 MEDLINE,并遵循了相应的国际建议。我们共确定了 42 篇文章,其中 23 篇被纳入。女性比例范围为 47%-75%,纳入的 10404 例总患者样本中女性的百分比为 65%。仅在纳入的 23 篇出版物中的 3 篇中对男性和女性亚群之间的主要变量进行了单独分析。相比之下,23 项试验中有 6 项按性别分析了次要变量。没有试验按性别分别讨论结果。纳入的女性比例略高于其他抗抑郁药临床试验中的比例。然而,对主要结果或次要变量按性别进行分析,以及分别按性别讨论结果的情况却很少。这使得这些研究工作中存在性别偏见。